⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

April 29, 2019Future OncologyOpen Access

How Can Better Identification of T790M Help to Inform Treatment Sequencing Decisions in EGFR Mutation-Positive Non-Small-Cell Lung Cancer?

Maximilian J. Hochmair

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Optimizing the detection of T790M after progression on first-/second-generation TKIs shouldallow more patients to benefit from subsequent osimertinib treatment."

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Maximilian J. Hochmair (2019) studied this question.

synapsesocial.com/papers/6aa528c686a9fcb249921a59 https://doi.org/10.2217/fon-2019-0142

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung CancerRCT · 2017 · 5,640 citations
2Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating MutationsRCT · 2018 · 440 citations
3Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentHuman Clinical Trial · 2017 · 571 citations
4Optimizing outcomes in <i>EGFR</i> Mutation-Positive Nsclc: Which Tyrosine Kinase Inhibitor and When?Original Research · 2018 · 103 citations
5Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung CancerOriginal Research · 2016 · 3,550 citations
6Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to OsimertinibCohort Study · 2018 · 106 citations
7Tumor Clonality and Resistance Mechanisms in <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic SequencingReview · 2018 · 117 citations
8Liquid Biopsies: Genotyping Circulating Tumor DNAOriginal Research · 2014 · 2,261 citations
9Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05Future Oncology · 2026
10Zanidatamab in the treatment of esophagogastric adenocarcinomaFuture Oncology · 2026

More from Future Oncology

More from Otto Wagner Hospital

More from Ludwig Boltzmann Institute for COPD And Respiratory Epidemiology